Further studies optimised the solubility and stability of the CLEC14A CTLD‐targeting antibodies and showed that they could block angiogenesis in mouse models utilising Matrigel plugs injected with recombinant VEGF or human tumour cells 206. This evidence concerns the gene VEGFA and neoplasm.